Single-probe Microwave Ablation (MWA) of Metastatic Liver Cancer

Overview

Microwave ablation (MWA) is the most recent development in the field of local ablative therapies. The aim of this study was to evaluate the variability and reproducibility of single-probe MWA versus radiofrequency ablation (RFA) of metastatic liver tumours smaller than 3 cm in patients without underlying liver disease.

Full Title of Study: “Single-probe Microwave Ablation of Metastatic Liver Cancer is Highly Variable and Irreproducible”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2009

Interventions

  • Device: Microwave ablation
    • Liver tumors are destructed/ablated using single-probe microwave energy device
  • Device: Radiofrequency ablation
    • Liver tumors are destructed/ablated using radiofrequency energy device

Arms, Groups and Cohorts

  • Experimental: MWA
    • Patients undergoing MWA for hepatic metastases smaller than 3 cm, without underlying liver disease
  • Active Comparator: RFA
    • Patients undergoing RFA for hepatic metastases smaller than 3 cm, without underlying liver disease

Clinical Trial Outcome Measures

Primary Measures

  • Variability of ablation diameters
    • Time Frame: within the first 7 days and 3 months after surgery

Participating in This Clinical Trial

Inclusion Criteria

  • Unresectable metastatic liver cancer – No invasion of major biliary structures – No invasion of major vascular structures – ASA score < 4 – WHO score 0-1 – Pre-operative chemotherapy is allowed Exclusion Criteria:

  • Resectable liver metastases – Life expectancy less than 3 months – Patients with cardiac pacemaker, cerebral aneurysm clips, implanted electronic instruments or other metal materials – Coagulopathy with platelet count less than 50000 – Active infectious disease – Age below 18 years – Pregnancy of breastfeeding

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Gasthuisberg
  • Provider of Information About this Clinical Study
    • University Hospital Gasthuisberg Leuven,
  • Overall Official(s)
    • Baki Topal, MD, PhD, Principal Investigator, Universitaire Ziekenhuizen KU Leuven

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.